Cover Image
市场调查报告书

注射型药物递输的欧洲市场 ~2020年:各类型 (设备、制剂) 、疗法 (荷尔蒙、肿瘤) 、利用模式、给药手法、终端用户的预测

European Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home care Setting) - Forecast to 2020

出版商 MarketsandMarkets 商品编码 275326
出版日期 内容信息 英文 247 Pages
订单完成后即时交付
价格
Back to Top
注射型药物递输的欧洲市场 ~2020年:各类型 (设备、制剂) 、疗法 (荷尔蒙、肿瘤) 、利用模式、给药手法、终端用户的预测 European Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home care Setting) - Forecast to 2020
出版日期: 2015年07月28日 内容信息: 英文 247 Pages
简介

欧洲的注射型药物递输市场,预计从2015年的1,147亿美元的规模,以年复合成长率 (CAGR) 12.6%成长,2020年达到2,073亿美元的规模。慢性疾病盛行率的上升、生技药品市场扩大、对自行注射设备的需求扩大,以及技术发展等要素,预期将促进该市场的成长。预计德国市场最急速成长,其高成长率由于胰岛素注射及自行注射型设备的需求增加,尤其是糖尿病的治疗上用于的笔型注射器的需求增加而具特徵。

本报告以欧洲的注射型药物递输市场为主题,提供市场概要、市场发展促进、阻碍因素、市场上课题及机会、各类型、适用疗法、利用模式、给药手法、终端用户、各国市场现况与展望相关调查分析、竞争环境、主要企业简介汇整。

第1章 简介

  • 调查目的
  • 市场定义
  • 市场范围
    • 网罗市场
    • 调查年份
  • 货币
  • 规定
  • 相关利益者

第2章 调查手法

  • 市场规模估计
  • 市场明细和数据的三角测量
  • 来自二级信息来源的主要数据
  • 来自一级信息来源的主要数据
  • 调查的前提条件

第3章 摘要整理

第4章 高级见解

  • 欧洲的注射型药物递输市场,各处方
  • 欧洲的注射型药物递输市场,各利用模式
  • 欧洲的注射型药物递输市场,各终端用户
  • 欧洲的注射型药物递输市场,各适用疗法

第5章 市场概要

  • 简介
  • 市场区隔
    • 各类型
    • 各适用疗法
    • 各利用模式
    • 各给药手法
    • 各终端用户
    • 各地区
  • 市场动态
    • 市场发展推动因素
      • 慢性疾病盛行率的上升
      • 对自行注射设备的需求扩大
      • 生技药品市场扩大
      • 技术发展
    • 市场发展阻碍因素
      • 针刺造成受伤及感染
      • 药物输送的替代手法出现
    • 市场机会
      • 对生物仿制药及非专利注射剂的需求扩大
        • 生物仿制药
        • 非专利注射剂
      • 避孕用注射剂
    • 课题
      • 产品的回收
      • 法规的门槛
      • 产品的稳定性
      • 注射的杀菌

第6章 欧洲的注射型药物递输市场,各类型

  • 简介
  • 设备
    • 传统注射设备
      • 各材料
      • 各产品
      • 各可用性
    • 自行注射设备
      • 无针注射器
      • 自行注射器
      • 笔型注射器
      • 穿戴式注射器
      • 其他设备
  • 处方
    • 传统药物递输
      • 溶液
      • 重组/冷冻乾燥制剂
      • 悬浮液
      • 乳浊液
    • 新的药物递输处方
      • 胶体分散
      • 微小粒子
    • 长时间作用型注射制剂

第7章 欧洲的注射型药物递输市场,各适用疗法

  • 简介
  • 自体免疫疾病
    • 类风湿性关节炎
    • 多发性硬化症
    • 克隆氏症
    • 乾癣
    • 其他的自体免疫疾病
  • 荷尔蒙伤害
    • 糖尿病
    • 贫血
    • 生殖相关疾病
    • 抗血栓/血栓溶解治疗
    • 骨质疏松症
    • 生长激素缺乏症 (GHD)
  • 罕见疾病
  • 肿瘤
  • 其他
    • 疼痛管理
    • 过敏的治疗
    • 美容治疗
    • C型肝炎
    • 血友病

第8章 欧洲的注射型药物递输市场,各利用模式

  • 简介
  • 治疗
  • 疫苗接种
  • 其他 (输血、血液制剂、避孕药)

第9章 欧洲的注射型药物递输市场,各给药手法

  • 简介
  • 皮肤
  • 循环/肌肉骨骼
  • 内脏器官
  • 中枢神经系统

第10章 欧洲的注射型药物递输市场,各终端用户

  • 简介
  • 医院、诊所
  • 居家医疗
  • 调查研究所
  • 制药及生物科技企业
  • 其他终端用户

第11章 欧洲的注射型药物递输市场,各国

  • 简介
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他欧洲

第12章 竞争环境

  • 概要
  • 市场占有率分析
  • 竞争情形、趋势
    • 新产品发表
    • FDA认证
    • 产业扩张、投资
    • 收购
    • 联盟、协定

第13章 企业简介 (业绩、产品与服务、主要策略、最近的动向)

  • 简介
  • BAXTER INTERNATIONAL, INC.
  • BECTON, DICKINSON AND COMPANY
  • GERRESHEIMER AG
  • PFIZER, INC.
  • SCHOTT AG
  • ALKERMES PLC.
  • ELI LILLY AND COMPANY
  • SANDOZ
  • Terumo Corporation
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

第14章 附录

  • 产业专家的观点
  • 讨论的指南
  • 其他最近的趋势
  • 可能的客制化
  • RT的介绍:即时 (RT) 市场信息
  • 相关报告

图表清单

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: BT 2073

The European injectable drug delivery market is expected to reach $207.3 billion by 2020 from $114.7 billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020. The market is categorized on the basis of type, therapeutic application, usage pattern, mode of administration, end user, and region. The therapeutic application market is further segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, and other therapeutic applications. The oncology segment is expected to witness the highest CAGR in the forecast period.

Factors such as rising incidences of chronic diseases, growth of the biologics market, demand of self-injection devices, and technological advancements, are driving the growth of the European injectable drug delivery market. In addition, Europe is emphasizing on innovation of formulations and improving the delivery of pharmaceuticals. For instance, in November 2012, COMPACT (Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets), a public-private consortium funded by the Innovative Medicines Initiative (IMI), announced the launch of a €30 million ($38.5 million) project, which focuses on improving the delivery of biopharmaceuticals. The consortium would address the major bottlenecks in the development of novel innovative medicines based on biological macromolecules, such as proteins/peptides and oligonucleotides. Such investments are fueling the growth of the market.

Germany is expected to be the fastest-growing country in the European injectable drug delivery market. High growth in this market can be attributed to the increased demand for injectable insulin and self-injection devices, particularly pen injectors which are used in the treatment of diabetes.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players in the European injectable drug delivery market and product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms to garner a greater market share. Firms purchasing the report can use one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the European injectable drug delivery market. The report analyzes this market by type, therapeutic application, usage pattern, mode of administration, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product launches in the European injectable drug delivery market
  • Competitive Assessment: In-depth assessment of market strategies, geographical and business segments, and product portfolios of leading players in the European injectable drug delivery market
  • Market Development: Comprehensive information about lucrative markets. The report analyzes the market for various European injectable drug delivery across countries
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the European injectable drug delivery market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. MARKET STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. KEY DATA FROM SECONDARY SOURCES
  • 2.4. KEY DATA FROM PRIMARY SOURCES
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION
  • 4.2. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
  • 4.3. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY END USER
  • 4.4. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. BY TYPE
    • 5.2.2. BY THERAPEUTIC APPLICATION
    • 5.2.3. BY USAGE PATTERN
    • 5.2.4. BY MODE OF ADMINISTRATION
    • 5.2.5. BY END USER
    • 5.2.6. BY REGION
  • 5.3. MARKET DYNAMICS
  • 5.4. DRIVERS
    • 5.4.1. RISING PREVALENCE OF CHRONIC DISEASES
    • 5.4.2. INCREASE IN DEMAND FOR SELF -INJECTION DEVICES
    • 5.4.3. GROWTH OF THE BIOLOGICS MARKET
    • 5.4.4. TECHNOLOGICAL ADVANCEMENTS
  • 5.5. RESTRAINTS
    • 5.5.1. NEEDLESTICK INJURIES AND INFECTIONS
    • 5.5.2. RISE OF ALTERNATE MODE OF DRUG DELIVERY
  • 5.6. OPPORTUNITIES
    • 5.6.1. INCREASE IN DEMAND FOR BIOSIMILARS AND GENERIC INJECTABLES
      • 5.6.1.1. Biosimilars
      • 5.6.1.2. Generic injectables
    • 5.6.2. CONTRACEPTIVE INJECTABLES
  • 5.7. CHALLENGES
    • 5.7.1. PRODUCT RECALL
    • 5.7.2. REGULATORY HURDLES
    • 5.7.3. STABILITY OF THE PRODUCT
    • 5.7.4. STERILITY OF INJECTIONS

6. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. DEVICES
    • 6.2.1. CONVENTIONAL INJECTION DEVICES
      • 6.2.1.1. By Material
        • 6.2.1.1.1. Glass
        • 6.2.1.1.2. Plastic
      • 6.2.1.2. By Product
        • 6.2.1.2.1. Fillable syringes
        • 6.2.1.2.2. Prefilled syringes
      • 6.2.1.3. By Usability
        • 6.2.1.3.1. Reusable syringes
        • 6.2.1.3.2. Disposable syringes
    • 6.2.2. SELF-INJECTION DEVICES
      • 6.2.2.1. Needle-free injectors
        • 6.2.2.1.1. By product
        • 6.2.2.1.1.1. Fillable needle-free injectors
        • 6.2.2.1.1.2. Prefilled needle-free injectors
        • 6.2.2.1.2. By technology
        • 6.2.2.1.2.1. Jet-based needle-free injectors
        • 6.2.2.1.2.2. Spring-based Needle-free injectors
        • 6.2.2.1.2.3. Laser-powered needle-free injectors
        • 6.2.2.1.2.4. Vibration-based needle-free injectors
        • 6.2.2.1.3. By usability
        • 6.2.2.1.3.1. Reusable needle-free injectors
        • 6.2.2.1.3.2. Disposable needle-free injectors
      • 6.2.2.2. Autoinjectors
        • 6.2.2.2.1. By product
        • 6.2.2.2.1.1. Fillable autoinjectors
        • 6.2.2.2.1.2. Prefilled autoinjectors
        • 6.2.2.2.2. By technology
        • 6.2.2.2.2.1. Automated Autoinjectors
        • 6.2.2.2.2.2. Manual Autoinjectors
        • 6.2.2.2.3. By design
        • 6.2.2.2.3.1. Standardized Autoinjectors
        • 6.2.2.2.3.2. Customized Autoinjectors
        • 6.2.2.2.4. By usability
        • 6.2.2.2.4.1. Reusable autoinjectors
        • 6.2.2.2.4.2. Disposable Autoinjectors
      • 6.2.2.3. Pen injectors
        • 6.2.2.3.1. By product
        • 6.2.2.3.1.1. Single-chambered Pen Injectors
        • 6.2.2.3.1.2. Dual-chambered Pen Injectors
        • 6.2.2.3.2. By design
        • 6.2.2.3.2.1. Standard Pen Injectors
        • 6.2.2.3.2.2. Customized Pen Injectors
        • 6.2.2.3.3. By usability
        • 6.2.2.3.3.1. Reusable Pen Injectors
        • 6.2.2.3.3.2. Disposable Pen Injectors
      • 6.2.2.4. Wearable injectors
      • 6.2.2.5. Other Devices
  • 6.3. FORMULATIONS
    • 6.3.1. CONVENTIONAL DRUG DELIVERY
      • 6.3.1.1. SOLUTIONS
      • 6.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
      • 6.3.1.3. SUSPENSIONS
      • 6.3.1.4. EMULSIONS
    • 6.3.2. NOVEL DRUG DELIVERY FORMULATIONS
      • 6.3.2.1. COLLOIDAL DISPERSIONS
        • 6.3.2.1.1. LIPOSOMES
        • 6.3.2.1.2. NIOSOMES
        • 6.3.2.1.3. POLYMERIC/MIXED MICELLE
        • 6.3.2.1.4. NANOPARTICLES
        • 6.3.2.1.4.1. NANOSUSPENSIONS
        • 6.3.2.1.4.2. NANOEMULSIONS/MICROEMULSIONS
        • 6.3.2.1.4.3. SOLID-LIPID NANOPARTICLES
      • 6.3.2.2. MICROPARTICLES
        • 6.3.2.2.1. MICROSPHERES
        • 6.3.2.2.2. MICROCAPSULES
    • 6.3.3. LONG-ACTING INJECTION FORMULATIONS

7. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION

  • 7.1. INTRODUCTION
  • 7.2. AUTOIMMUNE DISEASES
    • 7.2.1. RHEUMATOID ARTHRITIS
    • 7.2.2. MULTIPLE SCLEROSIS
    • 7.2.3. CROHN'S DISEASE
    • 7.2.4. PSORIASIS
    • 7.2.5. OTHER AUTOIMMUNE DISEASES
  • 7.3. HORMONAL DISORDERS
    • 7.3.1. DIABETES
    • 7.3.2. ANEMIA
    • 7.3.3. REPRODUCTIVE HEALTH DISEASE
    • 7.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
    • 7.3.5. OSTEOPOROSIS
    • 7.3.6. GROWTH HORMONE DEFICIENCY (GHD)
  • 7.4. ORPHAN DISEASES
  • 7.5. ONCOLOGY
  • 7.6. OTHERS
    • 7.6.1. PAIN MANAGEMENT
    • 7.6.2. ALLERGY TREATMENT
    • 7.6.3. AESTHETIC TREATMENT
    • 7.6.4. HEPATITIS C
    • 7.6.5. HEMOPHILIA

8. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

  • 8.1. INTRODUCTION
  • 8.2. CURATIVE CARE
  • 8.3. IMMUNIZATION
  • 8.4. OTHERS (BLOOD TRANSFUSION AND BLOOD PRODUCTS AND CONTRACEPTIVES)

9. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

  • 9.1. INTRODUCTION
  • 9.2. SKIN
  • 9.3. CIRCULATORY/MUSCULOSKELETAL
  • 9.4. ORGANS
  • 9.5. CENTRAL NERVOUS SYSTEM

10. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY END USER

  • 10.1. INTRODUCTION
  • 10.2. HOSPITALS AND CLINICS
  • 10.3. HOME CARE SETTINGS
  • 10.4. RESEARCH LABORATORIES
  • 10.5. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 10.6. OTHER END USERS

11. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY

  • 11.1. INTRODUCTION
    • 11.1.1. GERMANY
    • 11.1.2. FRANCE
    • 11.1.3. U.K.
    • 11.1.4. ITALY
    • 11.1.5. SPAIN
    • 11.1.6. REST OF EUROPE (ROE)

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MARKET SHARE ANALYSIS
  • 12.3. COMPETITIVE SITUATIONS & TRENDS
    • 12.3.1. NEW PRODUCT LAUNCHES
    • 12.3.2. FDA APPROVALS
    • 12.3.3. EXPANSIONS AND INVESTMENTS
    • 12.3.4. ACQUISITIONS
    • 12.3.5. COLLABORATIONS & AGREEMENTS

13. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 13.1. INTRODUCTION
  • 13.2. BAXTER INTERNATIONAL, INC.
  • 13.3. BECTON, DICKINSON AND COMPANY
  • 13.4. GERRESHEIMER AG
  • 13.5. PFIZER, INC.
  • 13.6. SCHOTT AG
  • 13.7. ALKERMES PLC.
  • 13.8. ELI LILLY AND COMPANY
  • 13.9. SANDOZ
  • 13.10. TERUMO CORPORATION
  • 13.11. TEVA PHARMACEUTICAL INDUSTRIES LTD.

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. OTHER RECENT DEVELOPMENTS
  • 14.4. AVAILABLE CUSTOMIZATIONS
  • 14.5. RT: REAL-TIME MARKET INTELLIGENCE
  • 14.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INCREASE IN DEMAND FOR SELF-INJECTION DEVICES IS BOOSTING THE MARKET GROWTH
  • TABLE 2: NEEDLESTICK INJURIES AND INFECTIONS ARE RESTRAINING THE MARKET GROWTH
  • TABLE 3: INCREASE IN DEMAND OF BIOSIMILARS OFFERS AN ARRAY OF OPPORTUNITIES FOR THE MARKET
  • TABLE 4: PRODUCT RECALL POSE SIGNIFICANT CHALLENGES TO MARKET GROWTH
  • TABLE 5: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 6: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 7: EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 8: EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE, 2013-2020 (MILLION UNITS)
  • TABLE 9: EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 10: EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 11: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 12: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 13: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY MATERIAL, 2013-2020 ($MILLION)
  • TABLE 14: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY MATERIAL, 2013-2020 (MILLION UNITS)
  • TABLE 15: EUROPE: CONVENTIONAL GLASS INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 16: EUROPE: CONVENTIONAL GLASS INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 17: EUROPE: CONVENTIONAL PLASTIC INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 18: EUROPE: CONVENTIONAL PLASTIC INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 19: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 20: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (MILLION UNITS)
  • TABLE 21: EUROPE: CONVENTIONAL FILLABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 22: EUROPE: CONVENTIONAL FILLABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 23: EUROPE: CONVENTIONAL PREFILLED INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 24: EUROPE: CONVENTIONAL PREFILLED INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 25: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY USABILITY, 2013-2020 ($MILLION)
  • TABLE 26: EUROPE: CONVENTIONAL INJECTION DEVICES MARKET SIZE, BY USABILITY, 2013-2020 (MILLION UNITS)
  • TABLE 27: EUROPE: CONVENTIONAL REUSABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 28: EUROPE: CONVENTIONAL REUSABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 29: EUROPE: CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 30: EUROPE: CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 31: EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 32: EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2013-2020 (MILLION UNITS)
  • TABLE 33: EUROPE: SELF-INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 34: EUROPE: SELF-INJECTION DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 35: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 36: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 37: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 38: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY PRODUCT, 2013-2020 (MILLION UNITS)
  • TABLE 39: EUROPE: FILLABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 40: EUROPE: FILLABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 41: EUROPE: PREFILLED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 42: EUROPE: PREFILLED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 43: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 44: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY TECHNOLOGY, 2013-2020 (MILLION UNITS)
  • TABLE 45: EUROPE: JET-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 46: EUROPE: JET-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 47: EUROPE: SPRING-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 48: EUROPE: SPRING-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 49: EUROPE: LASER-POWERED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 50: EUROPE: LASER-POWERED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 51: EUROPE: VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 52: EUROPE: VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 53: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY USABILITY, 2013-2020 ($MILLION)
  • TABLE 54: EUROPE: NEEDLE-FREE INJECTORS MARKET SIZE, BY USABILITY, 2013-2020 (MILLION UNITS)
  • TABLE 55: EUROPE: REUSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 56: EUROPE: REUSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 57: EUROPE: DISPOSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 58: EUROPE: DISPOSABLE NEEDLE-FREE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 59: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 60: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 61: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 62: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (MILLION UNITS)
  • TABLE 63: EUROPE: FILLABLE AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 64: EUROPE: FILLABLE AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 65: EUROPE: PREFILLED AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 66: EUROPE: PREFILLED AUTOINJECTOR DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 67: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY TECHNOLOGY, 2013-2020 ($MILLION)
  • TABLE 68: EUROPE: AUTOINJECTOR DEVICES MARKET SIZE, BY TECHNOLOGY, 2013-2020 (MILLION UNITS)
  • TABLE 69: EUROPE: AUTOMATED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 70: EUROPE: AUTOMATED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 71: EUROPE: MANUAL AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 72: EUROPE: MANUAL AUTOINJECTORS MARKET, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 73: EUROPE: AUTOINJECTORS MARKET SIZE, BY DESIGN, 2013-2020 ($MILLION)
  • TABLE 74: EUROPE: AUTOINJECTORS MARKET SIZE, BY DESIGN, 2013-2020 (MILLION UNITS)
  • TABLE 75: EUROPE: STANDARDIZED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 76: EUROPE: STANDARDIZED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 77: EUROPE: CUSTOMIZED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 78: EUROPE: CUSTOMIZED AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 79: EUROPE: AUTOINJECTOR MARKET SIZE, BY USABILITY, 2013-2020 ($MILLION)
  • TABLE 80: EUROPE: AUTOINJECTORS MARKET SIZE, BY USABILITY, 2013-2020 (MILLION UNITS)
  • TABLE 81: EUROPE: REUSABLE AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 82: EUROPE: REUSABLE AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 83: EUROPE: DISPOSABLE AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 84: EUROPE: DISPOSABLE AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 85: EUROPE: PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 86: EUROPE: PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 87: EUROPE: PEN INJECTORS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 88: EUROPE: PEN INJECTORS MARKET SIZE, BY PRODUCT, 2013-2020 (MILLION UNITS)
  • TABLE 89: EUROPE: SINGLE-CHAMBERED PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 90: EUROPE: SINGLE-CHAMBERED PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 91: EUROPE: DUAL-CHAMBERED PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 92: EUROPE: DUAL-CHAMBERED PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 93: EUROPE: PEN INJECTORS MARKET SIZE, BY DESIGN, 2013-2020 ($MILLION)
  • TABLE 94: EUROPE: PEN INJECTORS MARKET SIZE, BY DESIGN, 2013-2020 (MILLION UNITS)
  • TABLE 95: EUROPE: STANDARD PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 96: EUROPE: STANDARD PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 97: EUROPE: CUSTOMIZED PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 98: EUROPE: CUSTOMIZED PEN INJECTORS MARKET, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 99: EUROPE: PEN INJECTOR MARKET SIZE, BY USABILITY, 2013-2020 ($MILLION)
  • TABLE 100: EUROPE: PEN INJECTORS MARKET SIZE, BY USABILITY, 2013-2020 (MILLION UNITS)
  • TABLE 101: EUROPE: REUSABLE PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 102: EUROPE: REUSABLE PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 103: EUROPE: DISPOSABLE PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 104: EUROPE: DISPOSABLE PEN INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 105: EUROPE: WEARABLE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 106: EUROPE: WEARABLE INJECTORS MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 107: EUROPE: OTHER DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 108: EUROPE: OTHER DEVICES MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
  • TABLE 109: EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 110: EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 111: EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 112: EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 113: EUROPE: SOLUTIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 114: EUROPE: RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 115: EUROPE: SUSPENSIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 116: EUROPE: EMULSION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 117: EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 118: EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 119: EUROPE: COLLOIDAL DISPERSION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 120: EUROPE: COLLOIDAL DISPERSION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 121: EUROPE: LIPOSOMES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 122: EUROPE: NIOSOMES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 123: EUROPE: POLYMERIC/MIXED MICELLES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 124: EUROPE: NANOPARTICLES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 125: EUROPE: NANOPARTICLES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 126: EUROPE: NANOSUSPENSIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 127: EUROPE: NANOEMULSIONS/MICROEMULSIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 128: EUROPE: SOLID-LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 129: EUROPE: MICROPARTICLES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 130: EUROPE: MICROPARTICLES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 131: EUROPE: MICROSPHERES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 132: EUROPE: MICROCAPSULES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 133: EUROPE: LONG-ACTING INJECTION FORMULATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 134: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013 - 2020 ($MILLION)
  • TABLE 135: EUROPE: INJECTABLE DRUG DELIVERY THERAPEUTIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2013 - 2020 ($MILLION)
  • TABLE 136: EUROPE: AUTOIMMUNE DISEASES MARKET SIZE, BY INDICATION, 2013-2020 ($MILLION)
  • TABLE 137: EUROPE: AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 138: EUROPE: RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 139: EUROPE: MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 140: EUROPE: CROHN'S DISEASE MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 141: EUROPE: PSORIASIS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 142: EUROPE: OTHER AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 143: EUROPE: HORMONAL DISORDERS MARKET SIZE, BY INDICATION, 2013-2020 ($MILLION)
  • TABLE 144: EUROPE: HORMONAL DISORDERS MARKET SIZE, BY COUNTRY, 2013 -2020 ($MILLION)
  • TABLE 145: EUROPE: DIABETES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 146: EUROPE: ANEMIA MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 147: EUROPE: REPRODUCTIVE HEALTH DISEASE MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 148: EUROPE: ANTITHROMBOTIC/THROMBOLYTIC THERAPY MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 149: EUROPE: OSTEOPOROSIS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 150: EUROPE: GROWTH HORMONE DEFICIENCY (GHD) MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 151: EUROPE: ORPHAN DISEASES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 152: EUROPE: ONCOLOGY MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 153: EUROPE: OTHER THERAPEUTIC APPLICATIONS MARKET SIZE, BY INDICATION, 2013-2020 ($MILLION)
  • TABLE 154: EUROPE: OTHER THERAPEUTIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 155: EUROPE: PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 156: EUROPE: ALLERGY MANAGEMENT MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 157: EUROPE: AESTHETIC TREATMENT MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 158: EUROPE: HEPATITIS C MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 159: EUROPE: HEMOPHILIA MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 160: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013 - 2020 ($MILLION)
  • TABLE 161: EUROPE: USAGE PATTERN MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 162: EUROPE: CURATIVE CARE MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 163: EUROPE: IMMUNIZATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 164: EUROPE: OTHER USAGE PATTERNS MARKET SIZE, BY COUNTRY, 2013 - 2020 ($MILLION)
  • TABLE 165: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013 - 2020 ($MILLION)
  • TABLE 166: EUROPE: MODE OF ADMINISTRATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 167: EUROPE: SKIN ADMINISTRATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 168: EUROPE: CIRCULATORY/MUSCULOSKELETAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 169: EUROPE: ORGAN ADMINISTRATION MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 170: EUROPE: CENTRAL NERVOUS SYSTEM ADMINISTRATION, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 171: EUROPE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 172: EUROPE: END USER MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 173: EUROPE: HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 174: EUROPE: HOME CARE SETTING MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 175: EUROPE: RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 176: EUROPE: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 177: EUROPE: OTHER END USERS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 178: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 179: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 ($MILLION)
  • TABLE 180: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (MILLION UNITS)
  • TABLE 181: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 182: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 183: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 184: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 185: GERMANY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 186: FRANCE :INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 187: FRANCE :INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013 - 2020 ($MILLION)
  • TABLE 188: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013 - 2020 (MILLION UNITS)
  • TABLE 189: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 190: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE , BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 191: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 192: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 193: FRANCE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 194: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 195: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013 - 2020 ($MILLION)
  • TABLE 196: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (MILLION UNITS)
  • TABLE 197: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 198: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 199: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 200: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 201: U.K.: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 202: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 203: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE , BY DEVICE, 2013-2020 ($MILLION)
  • TABLE 204: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (MILLION UNITS)
  • TABLE 205: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 206: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 207: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 208: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 209: ITALY: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 210: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 211: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 ($MILLION)
  • TABLE 212: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (MILLION UNITS)
  • TABLE 213: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE , BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 214: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 215: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 216: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 217: SPAIN: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 218: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 219: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 ($MILLION)
  • TABLE 220: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY DEVICE, 2013-2020 (MILLION UNITS)
  • TABLE 221: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY FORMULATION, 2013-2020 ($MILLION)
  • TABLE 222: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2013-2020 ($MILLION)
  • TABLE 223: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY USAGE PATTERN, 2013-2020 ($MILLION)
  • TABLE 224: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY MODE OF ADMINISTRATION, 2013-2020 ($MILLION)
  • TABLE 225: ROE: INJECTABLE DRUG DELIVERY MARKET SIZE, BY END USER, 2013-2020 ($MILLION)
  • TABLE 226: NEW PRODUCT LAUNCHES (2012-2015)
  • TABLE 227: FDA APPROVALS (2012-2015)
  • TABLE 228: EXPANSIONS AND INVESTMENTS (2012-2015)
  • TABLE 229: ACQUISITIONS (2012-2015)
  • TABLE 230: COLLABORATIONS & AGREEMENTS (2012-2015)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE AND DESIGNATION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: EUROPEAN INJECTABLE DRUG DELIVERY MARKET SNAPSHOT, BY FORMULATION (2015 VS. 2020)
  • FIGURE 7: EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY DEVICES (2015-2020): SELF-INJECTION DEVICES TO WITNESS HIGHEST GROWTH RATE
  • FIGURE 8: HOSPITALS/CLINICS FORM THE LARGEST END-USER SEGMENT IN 2014
  • FIGURE 9: EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION (2015-2020): HORMONAL DISORDERS SEGMENT DOMINATES MARKET
  • FIGURE 10: EUROPEAN INJECTABLE DRUG DELIVERY FORMULATIONS MARKET TO GROW AT THE HIGHEST CAGR FROM 2015 TO 2020
  • FIGURE 11: THE CURATIVE CARE SEGMENT TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
  • FIGURE 12: HOME CARE SETTINGS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE IN 2015
  • FIGURE 13: HORMONAL DISORDERS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE MARKET IN 2015
  • FIGURE 14: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY TYPE
  • FIGURE 15: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY THERAPEUTIC APPLICATION
  • FIGURE 16: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY USAGE PATTERN
  • FIGURE 17: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY MODE OF ADMINISTRATION
  • FIGURE 18: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY END USER
  • FIGURE 19: INJECTABLE DRUG DELIVERY MARKET SEGMENTATION, BY REGION
  • FIGURE 20: RISING PREVALENCE OF CHRONIC DISEASES POPULATION WILL DRIVE THE MARKET GROWTH
  • FIGURE 21: EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2013 - 2020 ($MILLION)
  • FIGURE 22: THERAPEUTIC APPLICATIONS: GERMANY TO SHOW HIGHEST GROWTH
  • FIGURE 23: EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN: CURATIVE CARE TO HOLD LARGEST SHARE
  • FIGURE 24: EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION: SKIN SEGMENT TO SHOW HIGHEST GROWTH
  • FIGURE 25: EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER
  • FIGURE 26: EUROPE: EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY END USER: HOSPITALS/CLINICS TO HOLD LARGEST SHARE
  • FIGURE 27: EUROPE: FORMULATIONS MARKET SNAPSHOT
  • FIGURE 28: ROE: SELF-INJECTION DEVICES MARKET SNAPSHOT
  • FIGURE 29: KEY PLAYERS ADOPTED ORGANIC GROWTH STRATEGIES BETWEEN 2012 & 2015
  • FIGURE 30: GLOBAL INJECTABLE DRUG DELIVERY MARKET SHARE, BY KEY PLAYER (2014)
  • FIGURE 31: MARKET EVOLUTION FRAMEWORK: PARTNERSHIPS, AGREEMENTS AND COLLABORATIONS, & EXPANSIONS ARE FUELING MARKET GROWTH ,2014 &2015
  • FIGURE 32: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY LEADING PLAYERS FOLLOWED, 2013
  • FIGURE 33: PRODUCT BENCHMARKING FOR TOP 5 PLAYERS
  • FIGURE 34: BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT
  • FIGURE 35: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 36: GERRESHEIMER AG: COMPANY SNAPSHOT
  • FIGURE 37: PFIZER, INC.: COMPANY SNAPSHOT
  • FIGURE 38: SCHOTT AG: COMPANY SNAPSHOT
  • FIGURE 39: ALKERMES PLC: COMPANY SNAPSHOT
  • FIGURE 40: ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 41: SANDOZ: COMPANY SNAPSHOT
  • FIGURE 42: TERUMO CORPORATION: COMPANY SNAPSHOT
  • FIGURE 43: TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
Back to Top